We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 21-40 of 313 results

  1. Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid

    On page 2 of the original publication, in the section on TTR Silencers dosing of patisiran in the APOLLO study was stated as being given every...

    Augustus Hough, Jessica Wearden, ... Stephanie Kaiser in Current Cardiology Reports
    Article 28 September 2020

  2. Patisiran: First Global Approval

    Patisiran (ONPATTRO™) is a double-stranded small interfering RNA encapsulated in a lipid nanoparticle for delivery to hepatocytes. By specifically...

    Sheridan M. Hoy in Drugs
    Article 24 September 2018

  3. Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

    The original version of this article unfortunately contained a mistake.

    Alejandra González-Duarte, John L. Berk, ... David Adams in Journal of Neurology
    Article Open access 07 February 2020

  4. Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

    The middle initial of one of the authors, Alan Kaye, was missed in the original publication.

    Ivan Urits, Daniel Swanson, ... Omar Viswanath in Neurology and Therapy
    Article Open access 12 January 2021

  6. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

    Silencing the transthyretin ( TTR ) gene is an effective strategy in the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. Vutrisiran...

    Tina Nie, Young-A Heo, Matt Shirley in Drugs
    Article 20 September 2023

  8. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study

    Background

    There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR)...

    Taha N. Qarni, Felipe J. S. Jones, ... Chafic Karam in Orphanet Journal of Rare Diseases
    Article Open access 08 May 2024

  10. Update on Amyloid Polyneuropathy and Treatment

    Purpose of Review

    The purpose of this review is to summarize currently available and develo** diagnostic and treatment options for hereditary...

    Sasha A. Živković, J. David Avila, ... Dianna Quan in Current Treatment Options in Neurology
    Article 01 February 2024

  12. Kardiale Amyloidose

    Katharina Knoll, Patrick Fuchs, Teresa Trenkwalder in CardioVasc
    Article 31 March 2023

  14. Emerging Therapies for Transthyretin Amyloidosis

    Purpose of Review

    This review provides an overview of the available therapies for treating neuropathic and/or cardiac manifestations of transthyretin...

    Melissa R. Tsoi, Jeffrey H. Lin, Ayan R. Patel in Current Oncology Reports
    Article 21 March 2023

  15. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

    Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is an underrecognized cause of heart failure due to misfolded wild-type transthyretin...

    Danni Wu, Wei Chen in Heart Failure Reviews
    Article Open access 18 January 2024

  16. Advances in the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy

    Purpose of review

    Transthyretin amyloid cardiomyopathy (ATTR-CM) is a disease with high morbidity and mortality. This disease is significantly...

    Gabriela Spencer-Bonilla, Kevin M. Alexander, Ronald M. Witteles in Current Treatment Options in Cardiovascular Medicine
    Article 10 October 2020

  17. Kardiale ATTR-Amyloidose

    Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure and arrhythmia. This differential diagnosis should...

    Frauke Czepluch in Die Innere Medizin
    Article 04 August 2023

  18. Disease-Modifying Pharmacological Therapies for Transthyretin Cardiac Amyloidosis

    Transthyretin-related cardiac amyloidosis is a disease that is poorly understood and challenging to manage; however, pharmacotherapeutic developments...

    Jay H. Park, Laura F. Cei, Keyur B. Shah in SN Comprehensive Clinical Medicine
    Article 24 July 2020

  19. Peripheral neuropathy secondary to a ‘domino’ liver transplant: a case report

    Background

    Peripheral neuropathy caused by amyloidosis is one of the well-recognised sequelae of mutations in the transthyretin gene ( TTR ).

    ...
    Harriet A. Ball, James Stevens, Julian D. Gillmore in Journal of Medical Case Reports
    Article Open access 29 June 2023

  20. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence

    Background

    Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to...

    Ikponmwosa Jude Ogieuhi, Oshomoh Mark-Anthony Ugiomoh, ... Courage Idahor in The Egyptian Heart Journal
    Article Open access 10 July 2024
Did you find what you were looking for? Share feedback.